GridAI Technologies (GRDX) vs Serina Therapeutics (SER)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
GridAI Technologies (GRDX) has outperformed Serina Therapeutics (SER) over the past year, gaining 20.6% versus a loss of 71.9%. Over five years, SER leads with a -95.6% price change compared with -100.0% for GRDX. GridAI Technologies is the larger company by market cap ($32.4 million vs $29.8 million), about 1.1 times the size.
Serina Therapeutics converts more of its revenue into profit, with a net margin of -14755.4% versus -17634.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRDX | SER |
|---|---|---|
| Share price | $3.16 | $1.12 |
| Market cap | $32.44M | $29.76M |
| 1-day change | -8.41% | -6.67% |
| YTD return | -32.19% | -41.45% |
| 1-year return | +20.61% | -71.93% |
| 5-year return | -99.99% | -95.64% |
| EPS (TTM) | $-5.65 | $-1.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $36.25K | $130.00K |
| Revenue growth (YoY) | — | +132.14% |
| Net income (latest FY) | $-6.39M | $-19.18M |
| Gross margin | -1813.56% | — |
| Operating margin | -19539.98% | -18478.46% |
| Net margin | -17634.42% | -14755.38% |
| 52-week high | $6.93 | $4.26 |
| 52-week low | $1.87 | $1.06 |
| Distance from 52-week high | -54.39% | -73.71% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +748.21% |
| Average volume | 120.78K | 68.98K |
| Shares outstanding | 10.27M | 26.57M |
| Employees | — | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GRDX has outperformed SER by 92.5 percentage points over the past year.
- Serina Therapeutics is more profitable, keeping -14755.4 cents of every revenue dollar as net income versus -17634.4 cents for GridAI Technologies.
About GridAI Technologies
GRDX stock →GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency.
Health Care · Biotechnology: Pharmaceutical Preparations
About Serina Therapeutics
SER stock →Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
GRDX vs SER FAQ
Which is bigger, GridAI Technologies or Serina Therapeutics?
GridAI Technologies (GRDX) is larger, with a market capitalization of $32.44M compared with $29.76M for Serina Therapeutics (SER).
Which stock has performed better over the past year, GRDX or SER?
GRDX returned +20.61% over the past 12 months, compared with -71.93% for SER (price return, excluding dividends). Past performance does not predict future results.
Are GridAI Technologies and Serina Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.